Skip to main content
Midas Edge

Bone Biologics Corp

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

BBLG$0.34+3.0%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Unaudited Condensed Consolidated Statements of Stockholders’ Equity

Consolidated Statement of Stockholders’ Equity

For the Nine Months ended September 30, 2025

(unaudited)(1)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalEquityEquity
Balance at December 31, 2024492,417$492$88,504,543$(85,021,378)$3,483,657
Fair value of vested stock options--50,605-50,605
Options issued to settle accrued bonus--46,183-46,183
Issuance of common shares from ATM, net of costs of $13,02952,84353347,496-347,549
Net Loss---(1,017,092)(1,017,092)
Balance at March 31, 2025545,26054588,948,827(86,038,470)2,910,902
Fair value of vested stock options--72,899-72,899
Proceeds from sale of common stock and warrants in public offering, net of offering costs of $647,208793,7507944,351,998-4,352,792
Exercise of pre-funded warrants346,250346(346)--
Net Loss---(740,519)(740,519)
Balance at June 30, 20251,685,2601,68593,373,378(86,778,989)6,596,074
Fair value of vested stock options--87,180-87,180
Exercise of pre-funded warrants110,000110(110)--
Net Loss---(666,737)(666,737)
Balance at September 30, 20251,795,260$1,795$93,460,448$(87,445,726)$6,016,517
(1)Adjusted to reflect the reverse stock split as described in Note 1.

Consolidated Statement of Stockholders’ Equity

For the Nine Months ended September 30, 2024

(unaudited)(1)

Common Stock · Additional Paid-in · Accumulated · Total Stockholders’
SharesAmountCapitalEquityEquity
Balance at December 31, 202389,127$89$83,815,230$(80,908,958)$2,906,361
Fair value of vested stock options--52,681-52,681
Options issued to settle accrued bonus--77,400-77,400
Proceeds from sale of common stock in public offering, net of offering costs of $495,22719,833201,504,319-1,504,339
Exercise of pre-funded warrants60,5426077-137
Net Loss---(865,970)(865,970)
Balance at March 31, 2024169,50216985,449,707(81,774,928)3,674,948
Fair value of vested stock options--17,443-17,443
Exercise of pre-funded warrants49,83350249-299
Net Loss---(783,733)(783,733)
Balance at June 30, 2024219,335$219$85,467,399$(82,558,661)$2,908,957
Fair value of vested stock options--17,941-17,941
Issuance of common shares from warrant inducement, net of costs of $287,233130,2091301,806,390-1,806,520
Incremental value of warrant inducement--3,212,504-3,212,504
Deemed dividend on warrant inducement--(3,212,504)-(3,212,504)
Net Loss---(941,002)(941,002)
Balance at September 30, 2024349,544$349$87,291,730$(83,499,663)$3,792,416
(1)Adjusted to reflect the reverse stock split as described in Note 1.
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.